Peptide research profile

Cagrilintide

Also known as AM833 · Long-acting amylin analogue

An investigational long-acting amylin analogue studied once weekly for weight management, alone and with semaglutide.

  • Metabolic research
Human trials2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

Cagrilintide dosing remains investigational. Phase 2 research tested a broad weekly dose range with escalation. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Lower phase 2 arms0.3–0.6 mg / week
    26-week trial

    Lower maintenance arms in the dose-finding study.

  2. Mid phase 2 arms1.2–2.4 mg / week
    After escalation

    Includes the 2.4 mg dose used in combination research.

  3. Highest phase 2 arm4.5 mg / week
    After escalation

    Highest cagrilintide-only arm in the cited study; not an approved dose.

Schedule literacy

Patterns described in source material

  • Once weekly

    The clinical development program uses weekly administration.

  • Escalation

    The dose-finding trial included up to six weeks of dose escalation.

  • Combination-specific

    CagriSema schedules should not be interpreted as cagrilintide-only evidence.

Clinical context
  • 0.3–4.5 mg · Once weeklyPhase 2 dose-finding armsNCT03856047

Multiple doses have direct phase 2 human data, but the compound remains investigational.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Weight management

    A phase 2 dose-finding trial compared five weekly doses with placebo and liraglutide.

  • 02

    Appetite signaling

    Amylin pathways influence satiation and gastric emptying.

  • 03

    Combination research

    CagriSema studies combine cagrilintide with semaglutide.

  • 04

    Dose escalation

    Trials use escalation to reach maintenance exposures and manage tolerability.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Phase 2 dose-finding trial

    Weekly 0.3, 0.6, 1.2, 2.4, and 4.5 mg arms were studied for 26 weeks.

  • Human

    CagriSema phase 2 trial

    Cagrilintide 2.4 mg was studied with semaglutide 2.4 mg in type 2 diabetes.

  • Review

    Investigational status

    No cagrilintide-only product has an approved public dosing label.

Recorded protocol library

Amounts recorded for Cagrilintide

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Lower phase 2 arm

    0.3 mg

    Sign in for schedule, duration and source context.

  • 02

    Mid phase 2 arm

    2.4 mg

    Sign in for schedule, duration and source context.

  • 03

    Published phase 2 cap

    4.5 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Acylated amylin analogue
Origin / design
Engineered for prolonged amylin-receptor activity

Important limitations

  • Combination-trial results cannot be attributed to cagrilintide alone.
  • The calculator preset is not a substitute for the escalation used in trials.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Once-weekly cagrilintide for weight management in people with overweight and obesityThe Lancet · 2021 · Human
  2. Efficacy and safety of co-administered cagrilintide with semaglutide in type 2 diabetesThe Lancet · 2023 · Human

Related profiles